X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined company will work on an advanced pipeline with two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa in cystic fibrosis patients and BX211 for the treatment of diabetic foot osteomyelitis.
Lead Product(s): BX004
Therapeutic Area: Infections and Infectious Diseases Product Name: BX004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Adaptive Phage Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 18, 2024
Details:
The proceeds will fund Phase 2b that will evaluate BiomX’s lead product candidate, BX004, for the treatment of chronic pulmonary infections in CF patients and Phase 2 results from APT’s clinical-stage product candidate, BX211, for the treatment of S. aureus infections.
Lead Product(s): BX004
Therapeutic Area: Infections and Infectious Diseases Product Name: BX004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Deerfield Management Company
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 18, 2024
Details:
The combined company will work on an advanced pipeline with two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa in cystic fibrosis patients and BX211 for the treatment of diabetic foot osteomyelitis.
Lead Product(s): BX004
Therapeutic Area: Genetic Disease Product Name: BX004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Adaptive Phage Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 06, 2024
Details:
The proceeds will fund Phase 2b that will evaluate BiomX’s lead product candidate, BX004, for the treatment of chronic pulmonary infections in CF patients and Phase 2 results from APT’s clinical-stage product candidate, BX211, for the treatment of S. aureus infections.
Lead Product(s): BX004
Therapeutic Area: Infections and Infectious Diseases Product Name: BX004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Deerfield Management Company
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 06, 2024
Details:
BX004 is developed by utilizing company's proprietary BOLT platform, which is under phase 1/2 clinicaldevelopment for the treatment of chronic pulmonary infection caused by Pseudomonas aeruginosa in patients with cystic fibrosis.
Lead Product(s): BX004
Therapeutic Area: Infections and Infectious Diseases Product Name: BX004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
BX004 is a Microorganism solution for nebulizer, which works by targeting Chronic Pseudomonas Aeruginosa Infection in patients suffering from Cystic Fibrosis.
Lead Product(s): BX004
Therapeutic Area: Infections and Infectious Diseases Product Name: BX004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
BX004, utilizing its proprietary BOLT platform, for the treatment of CF patients with chronic pulmonary infections caused by P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
Lead Product(s): BX004
Therapeutic Area: Infections and Infectious Diseases Product Name: BX004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Details:
BiomX expects to use the aggregate net proceeds to fund clinical development of BX004 for the treatment of lung infections in patients with cystic fibrosis, the development of other programs, and research activities.
Lead Product(s): BX004
Therapeutic Area: Infections and Infectious Diseases Product Name: BX004
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: OrbiMed
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 05, 2023
Details:
BiomX expects to use the net proceeds from the PIPE to fund clinical development of BX004 for the treatment of lung infections in patients with cystic fibrosis, the development of other programs and research activities.
Lead Product(s): BX004
Therapeutic Area: Infections and Infectious Diseases Product Name: BX004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: OrbiMed
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 22, 2023
Details:
BX004 is active against antibiotic resistant strains of P. aeruginosa and demonstrated great biofilm penetration, an assemblage of surface-associated microbial cells enclosed in an extracellular polymeric substance the major causes for antibiotic resistance.
Lead Product(s): BX004
Therapeutic Area: Infections and Infectious Diseases Product Name: BX004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
